ArticleCureus2025
A Case of Anti-TIF1γ Antibody-Positive Dermatomyositis Associated With Malignancy.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dermatomyositis (DM) is a rare acquired autoimmune myopathy characterized by proximal muscle weakness, inflammation, and a typical skin rash. It is considered one of the idiopathic inflammatory myopathies (IIM), a group of heterogeneous systemic diseases that include DM, polymyositis, and inclusion body myositis. A significant portion of patients with IIM, particularly adults, can have an association with malignancy, usually preceded by muscle and skin symptoms. We report a case of a 67-year-old man who presented to the accident and emergency department with a six-week history of proximal myopathy in the upper and lower limbs and a skin rash. After a series of investigations, the patient was diagnosed with anti-TIF1γ-positive DM and concurrent lung cancer. DM is a paraneoplastic disorder that should always prompt a search for malignancy. Early detection of anti-TIF1γ autoantibodies can facilitate an early diagnosis of CAD, allowing for prompt therapeutic interventions. Several autoantibodies with different clinical and prognostic significance have been detected in IIM. However, the recently discovered anti-TIF1γ antibodies appear to be strongly associated with malignancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.